Serum Hepcidin Immunoassay - Laboratory to Marketplace

CompletedOBSERVATIONAL
Enrollment

494

Participants

Timeline

Start Date

June 30, 2016

Primary Completion Date

December 31, 2018

Study Completion Date

February 28, 2019

Conditions
Anemia, Iron Deficiency
Interventions
DIAGNOSTIC_TEST

Intrinsic Hepcidin IDx™ Test

ILS scientists developed the bioanalytical method for quantitation of human serum hepcidin using a Beckman FX automated liquid handling platform. The method uses a competitive ELISA format that has a proprietary sensitive and specific monoclonal antibody to hepcidin that captures native hepcidin in a sample. During the reaction a competition between a synthetic, bioactive, biotinylated hepcidin tracer and native hepcidin occurs. Bound biotinylated tracer is detected with a streptavidin-HRP conjugate and TMB substrate. Quantitation is based on an eight-point standard curve using validated, synthetic hepcidin calibrators. The standard curve and the hepcidin concentrations of patients samples are calculated using 4-parameter logistic curve fitting (Prism; Graphpad, Inc., La Jolla, CA). Serum hepcidin concentrations are expressed in ng/ml serum.

Trial Locations (1)

02115

Boston Children's Hospital, Boston

Sponsors
All Listed Sponsors
collaborator

Boston Children's Hospital

OTHER

lead

Intrinsic LifeSciences, LLC

INDUSTRY